EPISODE · Jun 4, 2021 · 5 MIN
Ponatinib Dosing Regimen Demonstrates Improved Responses, Survival in Patients With CP-CML
from Oncology Learning Network · host HMP Global
Jorge Cortes, MD, shares findings from the OPTIC trial on a dosing regimen of ponatinib for patients with CP-CML. These data are being presented at the 2021 ASCO Annual Meeting.
Embed this episode
Ready to play
Ponatinib Dosing Regimen Demonstrates Improved Responses, Survival in Patients With CP-CML
0:00
5:19
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of Oncology Learning Network?
This episode is 5 minutes long.
When was this Oncology Learning Network episode published?
This episode was published on June 4, 2021.
Can I download this Oncology Learning Network episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!